Acquisition and Placing

IP2IPO Group PLC
10 October 2005




For immediate release                               10 October 2005

                               IP2IPO GROUP PLC

      PROPOSED ACQUISITION OF TOUMAZ TECHNOLOGY LIMITED BY NANOSCIENCE INC


IP2IPO Group plc (AIM: IPO) ('IP2IPO'), the intellectual property
commercialisation company, is pleased to note that Nanoscience  Inc (AIM: NAN)
has announced that it has today conditionally agreed to acquire the entire
issued share capital of Toumaz Technology Limited ('Toumaz'), one of IP2IPO's
portfolio companies. Toumaz is also proposing to carry out a Placing to raise
£7.1 million before expenses which is due to complete immediately prior to the
acquisition of Toumaz



Toumaz develops ultra low power integrated circuits and silicon chips for use in
wireless and signal processing applications.  Nanoscience is a specialist
nanotechnology investment company which floated on AIM in March 2005.



The proposed acquisition, which is conditional upon the approval of Nanoscience
shareholders, values Toumaz at approximately £17.7 million based on the average
middle market price of shares in Nanoscience on the five business days prior to
the announcement. The consideration will be in shares in Nanoscience. IP2IPO has
a 5.3% shareholding in Toumaz and will have a 2.8% shareholding in the enlarged
Nanoscience share capital on completion of the acquisition which is due to occur
on 3rd November 2005.



For more information please contact:

IP2IPO                                                020 7489 5200
David Norwood, Chief Executive Officer

Buchanan Communications                               020 7466 5000
Tim Anderson, Mark Court



Notes for editors



IP2IPO is an intellectual property (IP) company that specialises in
commercialising university technology. The Company was founded in 2001 and
listed on the AIM Market of the London Stock Exchange plc in October 2003.
IP2IPO's first partnership was with the University of Oxford. In return for an
investment of £20 million, IP2IPO has acquired 50 per cent of the University of
Oxford's equity in spin-out companies and technology licenses based on
intellectual property created at the Chemistry Department until 2015. In
November 2003, IP2IPO created a £5 million seed capital fund for investing in
spin-out companies across the University of Oxford, not just those originating
within the Chemistry Department.



In March 2002, IP2IPO entered into a second long-term partnership with the
University of Southampton. Under the terms of this partnership, IP2IPO is
committed to working with the University of Southampton in the identification
and facilitation of spin-out companies from across the University of Southampton
and to investing £5 million in early-stage University of Southampton spin-out
companies over a four year period in return for equity stakes in those
companies. In addition, IP2IPO also received a 20 per cent stake in Southampton
Asset Management Limited, a company that has been formed to hold the
University's equity stakes in its spin-out companies. The partnership has a term
of at least 25 years.



IP2IPO entered into its third long-term partnership in May 2003 with King's
College London. IP2IPO will work with King's College London to help identify and
progress commercialisation opportunities as well as invest £5 million in seed
capital in spin-out companies from King's College London over a five year period
in return for equity stakes in those companies. In addition, IP2IPO will receive
20 per cent of King's College London's equity in spin-out companies and
technology licenses. The partnership has a term of 25 years.



In October 2003, IP2IPO announced a fourth partnership with the Centre for Novel
Agricultural Products ('CNAP'), based at the University of York. CNAP is a
flagship research centre that specialises in plant and microbial gene discovery.
Under the terms of the partnership a new company, Amaethon Limited, has been
created which has the right to commercialise CNAP's IP for 25 years. IP2IPO has
invested £1.15m in Amaethon Limited in return for a 40% equity stake in Amaethon
Limited (the remaining equity being owned by the University of York) and will
also invest in the spin-out companies based on CNAP's IP which Amaethon Limited
creates.



In June 2004, IP2IPO acquired Top Technology Ventures Limited, an investment
adviser to early stage technology funds. This combines IP2IPO's expertise in the
creation of new ventures based on world leading university IP with Top
Technology's focus on making early stage venture capital investments.



In January 2005, IP2IPO acquired Techtran, a company set up in 2002 to
commercialise university intellectual property under a long-term technology
commercialisation contract with the University of Leeds. Under the terms of the
contract Techtran receives a significant (30%) interest in spin-out companies
created and technology licences negotiated, in return for the provision of
technology transfer services to the University.



In May 2005, IP2IPO announced the launch of LifeUK, a new subsidiary company.
LifeUK, which has since been renamed Modern Biosciences, will in-license life
science intellectual property created by medical researchers at universities
with which IP2IPO already has partnerships, other universities in the UK and
similar academic and charitable research institutions. Modern Biosciences'
objective is to further develop the intellectual property which it in-licenses
with a view to creating substantial value either by subsequently licensing these
development programmes to the pharmaceutical industry or via the creation of new
ventures.



To date, 5 spin-out companies from the IP2IPO portfolio have listed on the AIM
Market of the London Stock Exchange plc: Offshore Hydrocarbon Mapping plc,
Synairgen plc, VASTox plc, Proximagen Neuroscience plc and GETECH Group plc.




                      This information is provided by RNS
            The company news service from the London Stock Exchange